Business Standard

Biocon rises on healthy Q3 earnings

Q3 net profit up 9% year-on-year at Rs 93 crore against an average analyst expectation of Rs 86 crore due to higher sales.

Related News

Biocon is trading higher by 4% to Rs 277 after reporting 9% year-on-year (yoy) rise in net profit at Rs 93 crore for the third quarter ended December 2012 (Q3) driven by period growth in different business verticals.

“Total sales of the company grew by 23% to Rs 635 crore from Rs 517 crore previous year,” said in a statement.

Analyst on an average had expected a net profit of Rs 86 crore and net sales of Rs 613 crore from the India’s largest biotechnology company by revenue.

“We have performed well across all our business verticals. We continue to gain market share for biosimilar insulins in global markets, which now accounts for a significant part of our business,” chairman and managing director said in a statement.

The company has received approval from the DCGI (Drugs Controller General of India) for our monoclonal antibody, Itolizumab, indicated for psoriasis. This is a significant milestone that enhances the value of this late-stage asset, added Kiran Mazumdar-Shaw.

The stock opened at Rs 268 and hit a high of Rs 278 on NSE. A combined 513,708 shares have already changed hands on the counter so far on both the exchanges.

 

Read more on:   
|
|

Biocon rises on healthy Q3 earnings

Q3 net profit up 9% year-on-year at Rs 93 crore against an average analyst expectation of Rs 86 crore due to higher sales.

Biocon is trading higher by 4% to Rs 277 after reporting 9% year-on-year (yoy) rise in net profit at Rs 93 crore for the third quarter ended December 2012 (Q3) driven by period growth in different business verticals.

Biocon is trading higher by 4% to Rs 277 after reporting 9% year-on-year (yoy) rise in net profit at Rs 93 crore for the third quarter ended December 2012 (Q3) driven by period growth in different business verticals.

“Total sales of the company grew by 23% to Rs 635 crore from Rs 517 crore previous year,” said in a statement.

Analyst on an average had expected a net profit of Rs 86 crore and net sales of Rs 613 crore from the India’s largest biotechnology company by revenue.

“We have performed well across all our business verticals. We continue to gain market share for biosimilar insulins in global markets, which now accounts for a significant part of our business,” chairman and managing director said in a statement.

The company has received approval from the DCGI (Drugs Controller General of India) for our monoclonal antibody, Itolizumab, indicated for psoriasis. This is a significant milestone that enhances the value of this late-stage asset, added Kiran Mazumdar-Shaw.

The stock opened at Rs 268 and hit a high of Rs 278 on NSE. A combined 513,708 shares have already changed hands on the counter so far on both the exchanges.

 

image

Read More

UCO Bank slips on declining net

Shares of UCO Bank has slumped after the bank posted a sharp drop in net profit for the third quarter ended December 31, 2012.

Recommended for you

Advertisements

Quick Links

Market News

Aluminium up by 0.7% on pick-up in demand

A firming trend in base metals at the London Metal Exchange (LME) also supported the rise in prices

Nickel rose by 1.4% on positive global cues

Speculators enlarged positions on positive cues from global markets

Igarashi Motors rallies on strong Q4 results

The stock rallied 9% to Rs 535 after reporting a 71% YoY jump in net profit at Rs 17.04 crore in the March 2015 quarter.

PNC Infratech declined below issue price

The stock had listed at Rs 387, a 2.4% premium against its issue price of Rs 378 per share; At 1004 hours, the stock was trading at Rs 377

Nifty hovers around 8,350; Tata Motors, ITC decline 1%

By 9:55, the Sensex was lower by 63 points at 27,581 and the Nifty has slipped by 17 points at 8,353

 

Back to Top